FDA Approves ISTA Drug for Treatment of Ocular Inflammation

ISTA Pharmaceuticals has received FDA approval for Xibrom, a topical, twice-daily, nonsteroidal anti-inflammatory solution intended to treat ocular inflammation following cataract surgery.

The company said it plans to launch Xibrom (bromfenac ophthalmic solution) during the second quarter of 2005, after securing commercial quantities of the product from its manufacturer and completing the further expansion of its sales force.